west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "放射性粒子" 4 results
  • Radioactive Seeds Iodine-125 Implantation in Treatment of Advanced Colorectal Cancer: Report of Nine Cases

    ObjectiveTo evaluate the viability, short-term clinical efficacy, and safety of ultrasound-guided radioactive seed 125I permanent implantation in tissue in patients with advanced colorectal cancer. MethodsA total of 9 patients were recruited in this study. All of the patients came from China-Japan Union Hospital of Jilin University from October 2012 to October 2014, which had been selected after strict screening. Five cases of male patients, 4 cases of female patients; the age was between 46-78 years old, the median age was 54 years old. There were 5 cases of patients with pain. There were 14 lesions in total, 1 lesion was local tumor recurrence, 2 lesions were pelvic metastasis, 8 lesions were liver metastases, and 3 lesions were abdominal lymph node metastasis. CEA increased in 6 cases before implantation. All patients were confirmed metastasis by CT, MRI examination or pathology. The 125I radioactive seed implantation was guided by real-time ultrasound. CT scanning was taken in two months after treatment. The degree of pain relief, tumor local control, and the occurrence of complications were observed. ResultsIn 2 months after implantation of 125I radioactive particles, the CT scanning results showed that 2 cases obtained complete response (CR), 5 cases obtained partial response (PR), 1 case got stable disease (SD), and 1 case got progress disease (PD). Total effective was 7/9, and disease control was 8/9. Five cases with pain symptoms were relieved after treatment. One walk metal particle in the abdominal cavity was found by abdominal CT scanning in 1 case. There were no serious complications intraoperative and postoperative. ConclusionsUltrasound guided radioactive seeds 125I implantation in the treatment of advanced colorectal cancer can significantly relieve the clinical symptoms, improve the quality of life, and can effectively control the metastasis. It is safe and feasible, and the postoperative hospitalization time is short, it has the avantages of safety, effectiveness, and low incidence of complications.

    Release date: Export PDF Favorites Scan
  • Efficacy of bronchoscopy-guided 125I seeds implantation combined with chemotherapy for advanced central type lung cancer

    Objective To explore the efficacy and safety of bronchoscopy-guided radioactive 125I seeds implantation combination with chemotherapy for advanced central type lung cancer. Methods Sixty-six patients with central type lung cancer in stage Ⅲb or Ⅳ were enrolled in this study from May 2014 to July 2016. The patients were randomly divided into two groups, ie. bronchoscopy-guided seeds implantation combined with chemotherapy group (experimental group, n=30) and chemotherapy group (control group, n=36). All patients accepted GP regimen (gemcitabine plus cisplatin) chemotherapy and were followed up by CT and electric bronchoscopy (EB) examination 1, 3, 5 months later. According to WHO unified standard, the efficacy and adverse effects were evaluated . Results In the experimental group and the control group, the response rate (complete response plus partial response) was 80.00% and 50.00%, respectively. There was significant difference between two groups (P<0.05). The incidence rate of hemoptysis in the experimental group was significantly higher than that in the control group (P<0.05), but there was no significant difference between the two groups in the incidence rate of pneumothorax, fever or bone marrow suppression (allP>0.05). All adverse reactions were light and could be controlled. Conclusions The short-term clinical efficacy is better in the bronchoscopy-guided seeds implantation combined with chemotherapy group. The bronchoscopy-guided seeds implantation combined with chemotherapy is a safe and minimally invasive treatment for advanced central type lung cancer.

    Release date:2017-11-23 02:56 Export PDF Favorites Scan
  • 尼达尼布治疗放射性肺损伤一例并文献复习

    目的探讨放射性肺损伤的发病机制、临床表现、影像学特点、可能的治疗手段及预后。方法分析 1 例确诊为肺鳞癌合并放射性肺损伤并接受尼达尼布治疗患者的临床资料,结合相关文献复习,总结其临床特点、治疗过程及预后。结果本例为 72 岁男性肺鳞癌患者,经同步放化疗和放射性粒子植入术后并发放射性肺损伤,主要症状为活动后气促,胸部 CT 表现为双肺磨玻璃影和网格影,右下肺显著。经尼达尼布规范化治疗 4 个月后,临床症状以及影像学都明显缓解,随访 1 年,病情持续稳定,未见明显不良反应。文献复习发现,放射性肺损伤患者临床上多表现为干咳、发热及呼吸困难,重症患者可危及生命,影像学多表现为放射靶区的片状影,多以肺实变伴支气管充气征为主。最常用的治疗药物为糖皮质激素,也有少部分患者对激素治疗反应不佳,新的治疗手段仍在探索之中。结论放射性肺损伤是恶性肿瘤患者放疗过程中较常见的并发症,但目前治疗手段有限,尼达尼布作为一种新型的小分子靶向药,可能对放射性肺损伤具有一定的修复作用。

    Release date: Export PDF Favorites Scan
  • 光动力疗法联合胆道支架与125I粒子支架在不可切除肝外胆管癌的疗效对比研究

    目的对比分析光动力疗法(photodynamic therapy,PDT)联合胆道支架和125I粒子支架治疗晚期肝外胆管癌患者的疗效。 方法回顾性收集2015年1月1日至2023年12月31日期间新疆医科大学第一附属医院收治的32例肝门部胆管癌(Bisnmuth Ⅰ ~Ⅱ型)或胆总管中下段癌患者的临床资料,根据治疗方法的不同分为PDT联合胆道支架组(简称PDT+支架组,9例)和125I粒子支架组(23例),比较2组患者在手术时间、总住院时间、术后并发症发生率、支架通畅时间和生存时间方面的差异。 结果PDT+支架组的手术时间为(83.00±38.40)min,125I粒子支架组的手术时间为(73.70±30.12)min,PDT+支架组的手术时间略长于125I粒子支架组,但差异无统计学意义(P=0.471); PDT+支架组的总住院时间长于125I粒子支架组 [15.0(11.5,17.5)d 比 9.0(7.0,12.0)d],2组间的差异有统计学意义(P=0.038)。PDT+支架组术后出现并发症2例(22.2%),125I粒子支架组术后出现并发症3例(13.0%),2组间的差异无统计学意义(P=0.604)。PDT+支架组的中位支架通畅时间和中位生存时间均长于125I粒子支架组 [8.0(4.5,10.0)个月比 7.0(4.0,11.0)个月;10.0(7.3,13.5)个月比 8.0(5.0,12.0)个月],但2组间的差异均无统计学意义(P>0.05)。结论单次PDT联合胆道支架治疗晚期胆管癌在延长支架通畅时间和生存时间方面具有一定优势,但其有效性和安全性与125I粒子支架治疗差异并不显著。

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content